Obesity Drug Development Summit Europe on October 01-02, 2025 in Barcelona, Spain

The Obesity Drug Development Summit Europe is set to be the leading industry-focused event for advancing next-generation obesity therapies. Taking place in Barcelona, Spain, from the 1st to 2nd of October 2025, this inaugural summit will bring together over 50 leaders from pharma, biotech, and academia. Attendees will address critical challenges in obesity care, including lean mass preservation, patient stratification, scalable manufacturing, and payer-driven endpoints.

This event offers a unique opportunity to explore cutting-edge therapies such as GIPR modulators, DNA-encoded treatments, and RNA-based therapies, which aim to achieve metabolic transformation beyond simple weight loss. Participants will gain insights into designing clinical trials that align with payer expectations by leveraging real-world evidence and precision biomarkers, with contributions from industry leaders like Novo Nordisk. The summit will also delve into optimizing combination therapies, including GLP-1-based regimens with myostatin inhibitors and amylin analogues, to enhance efficacy and muscle preservation.

With innovations in oral formulations and long-acting injectables from companies like Ambrosia Biosciences and Cytoki Pharma, manufacturing challenges will be addressed head-on. As the obesity therapeutics market evolves rapidly, this summit is a vital platform to collaborate, benchmark, and shape the future of obesity care through precision medicine and sustainable drug development.

URLs:

Tickets: https://go.evvnt.com/3112981-2?pid=10008

Brochure: https://go.evvnt.com/3112981-3?pid=10008

Time: 7:30 AM - 3:30 PM

Prices:

Drug Developer Pricing - 2 Day Conference: EUR 2799.00,

Academic Pricing - 2 Day Conference: EUR 2399.00,

Solution Provider Pricing - 2 Day Conference: EUR 3399.00

Speakers: Ann Beliën, Chief Executive Officer, Rejuvenate Biomed, Steffen-Sebastian Bolz, Chief Scientific Officer and Executive Board Member, Aphaia Pharma, Matthew Coghlan, Interim Portfolio Science Lead, Eli Lilly and Company, Marek Drozdz, Director of Research, RenBio, Zach Gerhart-Hines, Chief Technology Officer and Associate Professor at CBMR, Embark Laboratories / University of Copenhagen, Ulf Holmbäck, Chief Scientific Officer, Empros Pharma, Patrice Lee, Vice President, Research and Development, Ambrosia Biosciences, Philip Larsen, Chief Executive Officer, Six Peaks Bio, Sophie Jeannin Megnien, Chief Medical Officer, Northsea Therapeutics, Timo Müller, Director, Institute for Diabetes and Obesity, Helmholtz Zentrum München, Riccardo Panella, Founder and Chief Scientific Officer, Resalis Therapeutics, Cory Schwartz, Director, Drug Discovery, iBio, Arvid Soderhall, Chief Executive Officer, Empros Pharma, Martijn van de Bunt, Chief Scientific Officer, Cytoki Pharma, Joanne Young, Scientific Director, Cytoo, Daniel Markgraf, Head of Laboratory, Boehringer Ingelheim, Yajing Zhu, Vice President, Department of Real World Evidence: Obesity and Liver, Novo Nordisk